<DOC>
	<DOCNO>NCT02195791</DOCNO>
	<brief_summary>Pioglitzone , oral anti-diabetic drug reduce insulin resistance decrease inflammation . It proven effective neuroprotective agent animal model ischemic stroke . In study , investigator conduct phase II clinical trial ( double-blind , randomized placebo control study ) survey neuroprotection effect pioglitazone stroke patient hyperglycemia . A total 152 acute ischemic stroke patient hyperglycemic receive insulin sulfonyurea blood sugar control , randomly randomize intervention ( Pioglitazone 30mg day p.o , ) control group ( placebo ) . The investigator expect prove neuroprotective efficacy Pioglitazone acute stroke hyperglycemia identify biomarkers associate good neurological outcome patient Pioglitazone treatment investigator clinical trial .</brief_summary>
	<brief_title>Neuroprotection Pioglitazone Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Acute ischemic stroke onset within 48 hour 2 . Age≧20 year 3 . Stroke severity least one point limb weakness National Institutes Health Stroke Scale ( NIHSS ) . 4 . The patient know history diabetes admission serum glucose ≧130 mg/dl . 1 . The patient history urinary bladder cancer hematuira . 2 . The patient history congestive heart failure myocardial infarction . 3 . The patient know history use pioglitazone onset stroke . 4 . The patient mRS≧3 stroke onset .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>